Latest period
$0.00
YoY change
—
5Y CAGR
-100.0%
Peak year (2022)
$619.00M
Latest annual
$0.00
Stock-Based Compensation history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $0.00
Stock-Based Compensation growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: -100.0%
Stock-Based Compensation history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $0.00 | — | $0.00 | ||
| 2024 | $0.00 | -100.0% | −$579.00M | ||
| 2023 | $579.00M | -6.5% | −$40.00M | ||
| 2022 | $619.00M | +0.7% | +$4.00M | ||
| 2021 | $615.00M | +122.0% | +$338.00M | ||
| 2020 | $277.00M | +6.9% | +$18.00M | ||
| 2019 | $259.00M | — | +$259.00M | ||
| 2018 | $0.00 | — | $0.00 | ||
| 2017 | $0.00 | — | $0.00 | ||
| 2016 | $0.00 | — | $0.00 | ||
| 2015 | $0.00 | — | $0.00 | ||
| 2014 | $0.00 | — | $0.00 | ||
| 2013 | $0.00 | — | $0.00 | ||
| 2012 | $0.00 | — | $0.00 | ||
| 2011 | $0.00 | — | $0.00 | ||
| 2010 | $0.00 | — | $0.00 | ||
| 2009 | $0.00 | — | $0.00 | ||
| 2008 | $0.00 | — | $0.00 | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | $0.00 | ||
| 1998 | $0.00 | — | $0.00 | ||
| 1997 | $0.00 | — | $0.00 | ||
| 1996 | $0.00 | — | $0.00 | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | — | $0.00 | ||
| 1992 | $0.00 | — | $0.00 | ||
| 1991 | $0.00 | — | $0.00 | ||
| 1990 | $0.00 | — | — |
- 2025$0.00—
- 2024$0.00-100.0%
- 2023$579.00M-6.5%
- 2022$619.00M+0.7%
- 2021$615.00M+122.0%
- 2020$277.00M+6.9%
- 2019$259.00M—
- 2018$0.00—
- 2017$0.00—
- 2016$0.00—
- 2015$0.00—
- 2014$0.00—
- 2013$0.00—
- 2012$0.00—
- 2011$0.00—
- 2010$0.00—
- 2009$0.00—
- 2008$0.00—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
- 1998$0.00—
- 1997$0.00—
- 1996$0.00—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00—
- 1992$0.00—
- 1991$0.00—
- 1990$0.00—
Stock-Based Compensation values are taken from AstraZeneca's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at AstraZeneca (AZN)
Stock-Based Compensation for AstraZeneca (AZN): headline value $0.00. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, AstraZeneca (AZN) stock-based compensation totalled $0.00.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca stock-based compensation compounded at -100.0% per year, with a net decline across the window.
Across the available history, stock-based compensation reached its high of $619.00M in 2022 and its low of $0.00 in 1990.
AstraZeneca Stock-Based Compensation by Year
AstraZeneca Stock-Based Compensation 2025: $0.00
AstraZeneca stock-based compensation in 2025 was $0.00.
AstraZeneca Stock-Based Compensation 2024: $0.00
AstraZeneca posted stock-based compensation of $0.00 in 2024, plunged 100.0% below 2023.
AstraZeneca Stock-Based Compensation 2023: $579.00M
In 2023, AstraZeneca reported stock-based compensation of $579.00M, declined 6.5% below 2022.
AstraZeneca Stock-Based Compensation 2022: $619.00M
AstraZeneca stock-based compensation in 2022 was $619.00M, edged up 0.7% from 2021. This figure represents the highest annual value in the available history.
AstraZeneca Stock-Based Compensation 2021: $615.00M
AstraZeneca stock-based compensation in 2021 was $615.00M.
See more financial history for AstraZeneca (AZN).
Sector peers by Stock-Based Compensation
Healthcare peers of AstraZeneca (AZN), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $310.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $310.00M
- $0.00
- $0.00
- $0.00
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation